調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025

C型肝炎(Hepatitis C)治療薬の世界市場

◆タイトル：Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025
◆商品コード：VGAIN4121902
◆調査・発行会社：visiongain
◆発行日：2014年12月
◆ページ数：196
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserGBP1,799 ⇒換算￥278,845見積依頼/購入/質問フォーム
Five UsersGBP2,999 ⇒換算￥464,845見積依頼/購入/質問フォーム
Site License（全社内共有可）GBP4,999 ⇒換算￥774,845見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、C型肝炎(Hepatitis C)治療薬の世界市場について調査・分析し、レポートサマリー、市場概要、世界市場分析（市場規模、市場予測、促進要因、抑制要因）、セグメント別分析、研究開発パイプライン、主要地域別分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。

Hepatitis C treatments – your guide to medical needs, R&D trends and future drug revenues
Discover the future of treating hepatitis C virus (HCV). Now you can get sales forecasts and explore that industry’s research and development. See where the money lies from 2014. And find where that technology heads.

Visiongain’s new guide predicts those revenues to 2025 at overall world, submarket, product and national level. Its purpose is to help you stay ahead in data, news and analysis on those therapies. It examines medical, technological and commercial potentials and opportunities.

Can that that large, profitable market sustain revenue growth? Please read on to explore HCV medicines and their producers, seeing how high that industry’s sales can go.

Forecasts and other analyses to help your research, knowledge and influence
Avoid struggles to find business information on that viral infection. Instead discover what’s happening in technology and demand for therapy. With our investigation you can make your research, appraisals and commercial decisions on hepatitis C treatments quicker and easier.
• Who is the company with the highest expected revenue from 2015 to 2025?
• What technologies give the most promising candidates for new drugs?
• Where lie the best geographical opportunities for selling those antivirals?
• Why will the HCV drug market expand, and what limits its sales growth?
• When will that industry achieve fastest expansion and peak revenues?
• How will companies overcome challenges in serving regulators, patients and payers?

Besides sales predictions to 2025, our study presents recent results, growth rates, market shares and discussions. You get 69 tables, 53 charts and two interviews with authorities.

Forecasting of the world HCV therapy market and its segments
Our report predicts overall world revenue to 2025 for those anti-infective drugs. There you also find individual revenue predictions to 2025 for two submarkets at world level:
• Oral antiviral agents
• Interferons for treating that disorder.

For treating that infectious disease, especially of the liver, discover how competition and technological advances shape the industry. So benefit your reputation for commercial knowledge. And find where the most money and best prospects for commercial growth exist.

Also assess leading pharmaceutical brands for tackling those chronic infections.

Forecasts for HCV medicines – see potentials for top brands
How will six leading and three emerging drugs perform to 2025 at world level? Our study forecasts individual revenues of nine agents:
• Sovaldi (sofosbuvir)
• Olysio (simeprevir)
• Pegasys (peginterferon alfa-2a)
• Incivek and related brands (telaprevir)
• PegIntron (peginterferon alfa-2b)
• Victrelis (boceprevir)
• Harvoni (ledipasvir and sofosbuvir)
• Daklinza (daclatasvir)
• Sunvepra (asunaprevir).

Those analyses show you how high sales can go. There find products and years with highest predicted expansion and revenues. You hear what’s happening. And you deepen your understanding of trends, competition, challenges and opportunities.

In that work you also find national revenue predictions.

Healthcare in regional markets – what outlooks for that business?
Our investigation also shows you individual revenue forecasts to 2025 for 11 countries:
• United States (US)
• Japan
• Germany, France, UK, Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that industry and market?

Forces, events and issues – developments influencing those antiviral treatments
That new report explains policies, trends and R&D shaping the industry and market, including these influences:
• Protease, polymerase and NS5A inhibitors, interferons, vaccines and other agents – explore drug development, viewing prospects for future therapies
• Combination therapy – hepatitis C treatment via interferons and antivirals
• Interferon-free regimens, prophylactic and personalised medicine tackling genotypes
• Direct-acting antivirals (DAAs) – a change in therapeutic procedures
• Generics and biosimilars – rising competition for original brands, including follow-on biological drugs
• Licensing, partnering and acquisition deals – collaborations among developers, manufacturers and marketers.

There you assess that industry’s strengths, weaknesses, opportunities and threats. Also explore social, technological, economic and political questions. Those analyses give you feel for that market – its progress, potential and opportunities, reducing your risk of falling behind.

Developers, manufacturers, sellers and 2018 market value – what happens next?
From 2015 HCV treatments hold great potential for investments, technologies, medical advances and sales. Our analyses predict the overall world market for those products will reach $32bn in 2018, with high revenues from 2014 to 2025.

That work also explores activities and potentials of these companies in particular:
• Gilead Sciences
• Janssen Pharmaceutica
• Roche
• Bristol-Myers Squibb
• Merck & Co.
• AbbVie
• Achillion Pharmaceuticals.

【レポートの目次】

1. Report Overview
1.1 Overview of the World Market for Hepatitis C Therapies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Hepatitis C Therapies
2.1 A Brief History of Hepatitis C and Treatments
2.1.1 Genotypes
2.1.2 Symptoms: Acute and Chronic Hepatitis C
2.1.3 Diagnosing Hepatitis C: The Asymptomatic Nature
2.1.4 Risk Factors for Hepatitis C
2.2 Incidence and Prevalence Patterns
2.3 Hepatitis C: Treatment and Prevention
2.3.1 Antivirals: Inhibiting Virus Replication
2.3.1.1 Protease Inhibitors
2.3.1.2 Polymerase Inhibitors
2.3.1.3 NS5A Replication Complex Inhibitors
2.3.2 Interferons: Dual Mode of Action
2.3.2.1 Combination Therapy: Treatment with Interferons and Antivirals
2.3.2.2 Interferon-Free Regimens
2.3.3 Hepatitis C and the Need for a Vaccine

3. The World Hepatitis C Therapies Market, 2015-2025
3.1 Hepatitis C Therapies Market, 2013 and 2014
3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2014-2025
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis C Therapies Market
3.2.3 Biosimilar Interferons
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket
3.3.1 Oral Antivirals Submarket: Revenue Forecast, 2014-2025
3.3.2 A Strong Developmental Pipeline to Drive Market Growth
3.3.3 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2013
3.4.4 Interferons Submarket: Revenue Forecast, 2014-2025
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis C Vaccines Submarket
3.6 Hepatitis C Therapies: Submarket Shares 2013, 2019 and 2025

4. Leading National Hepatitis C Markets, 2015-2025
4.1 Global Prevalence of Hepatitis C, 2013
4.1.1 The Importance of Asia
4.2 Hepatitis C Therapies Market: Regional Breakdown, 2013
4.3 Hepatitis C Therapies Market: Regional Forecast, 2014-2025
4.4 The US
4.4.1 Population Movement and Hepatitis C
4.4.2 The Affordable Care Act and Hepatitis C
4.4.3 Increased Screening towards Target Population
4.4.4 The US Revenue Forecast, 2014-2025
4.5 Leading EU Markets for Hepatitis C Therapies
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2013
4.5.3 EU5: Revenue Forecasts, 2014-2025
4.5.4 Italy: Revenue Forecast, 2014-2025
4.5.5 Spain: Revenue Forecast, 2014-2025
4.5.6 Germany: Revenue Forecast, 2014-2025
4.5.7 UK: Revenue Forecast, 2014-2025
4.5.8 France: Revenue Forecast, 2014-2025
4.6 Hepatitis C in Asia
4.7 China
4.7.1 Decline in Incidence of Hepatitis C
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2014-2025
4.8 Japan
4.8.1 Hepatitis C in Japan
4.8.2 Japan: Revenue Forecast, 2014-2025
4.9 India
4.9.1 Low Awareness Rates
4.9.2 India: Revenue Forecast, 2014-2025
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Adverse Impact of Western Sanctions on Russian Pharma Market
4.10.3 Russia: Revenue Forecast, 2014-2025
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2014-2025

5. Leading Hepatitis C Therapies, Market Prospects to 2025
5.1 Leading Hepatitis C Therapies, 2014-2025
5.2 Sovaldi (Gilead Sciences)
5.2.1 Recent Revenue Analysis
5.2.2 Gilead Licenses Generic Substitute for Sovaldi for Developing Countries
5.2.3 Sovaldi Revenue Forecast, 2014-2025
5.3 Olysio (Janssen/Medivir)
5.3.1 Recent Revenue Analysis
5.3.2 Combination Regimen of Sovaldi and Olysio
5.3.3 Olysio Revenue Forecast, 2014-2025
5.4 Pegasys (Roche)
5.4.1 Recent Revenue Analysis
5.4.2 Label Expansions and Lifecycle Management Strategies
5.4.3 Pegasys Revenue Forecast, 2014-2025
5.5 Incivek (Vertex/Janssen (J&J)/Mitsubishi Tanabe)
5.5.1 Recent Revenue Analysis
5.5.2 Targeting HCV/HIV Co-Infected Patients
5.5.3 Pipeline Competition May Affect Revenues
5.5.4 Incivek Revenue Forecast, 2014-2025
5.6 PegIntron (Merck & Co.)
5.6.1 Recent Revenue Analysis
5.6.2 Competition from Interferon Biosimilars
5.6.3 Enhancing Drug Life Cycle
5.6.4 PegIntron Revenue Forecast, 2014-2025
5.7 Victrelis (Merck & Co.)
5.7.1 Recent Revenue Analysis
5.7.2 Roche Collaboration
5.7.3 Product Differentiation
5.7.4 Victrelis Revenue Forecast, 2014-2025
5.8 Harvoni (Gilead Sciences)
5.8.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
5.8.2Harvoni Revenue Forecast, 2014-2025
5.9 Daklinza (Bristol-Myers Squibb)
5.9.1 Daklinza Revenue Forecast, 2014-2025
5.10 Sunvepra (Bristol-Myers Squibb)
5.10.1 Sunvepra: Synergistic Effect with Daklinza
5.10.2 Sunvepra Revenue Forecast, 2014-2025

6. Hepatitis C Therapies Market: Leading R&D Pipeline Candidates, 2014
6.1 Introduction to Hepatitis C Therapy Candidates
6.2 Protease Inhibitors Pipeline
6.2.1 Vaniprevir (Merck & Co.): Patent Security through 2027
6.2.2 MK-5172 and MK-8742 (Merck & Co.): Phase III
6.2.3 Paritaprevir (formerly ABT-450) (AbbVie): Fast-Tracked into Phase III
6.2.4 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
6.2.5 ACH-2684 (Achillion Pharmaceuticals)
6.2.6 Danoprevir (Roche): Testing Out Combination Regimens
6.2.7 Lomibuvir (Vertex Pharmaceuticals)
6.2.8 ABT-493 (AbbVie)
6.2.9 Vedroprevir (Gilead Sciences)
6.2.10 GS-9857 (Gilead Sciences)
6.3 Polymerase Inhibitors Pipeline
6.3.1 ACH-2928 (Achillion Pharmaceuticals)
6.3.2 BMS-791325 (Bristol-Myers Squibb): Phase II
6.3.3 TMC-647055 (Janssen): Phase II
6.3.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
6.3.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
6.3.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
6.3.7 GS-9669 (Gilead Sciences)
6.3.8 PPI-383 (Presidio Pharmaceuticals)
6.4 NS5A Inhibitors Pipeline
6.4.1 ABT-530 (AbbVie)
6.4.2 Samatisvir (Merck & Co.): Acquired from Idenix
6.4.3 GS-5816 (Gilead Sciences)
6.4.4 PPI-668 (Presidio Pharmaceuticals)
6.5 Interferon Pipeline
6.5.1 Locteron (Biolex): Controlled Release Formulation
6.5.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
6.6 Novel Inhibitors
6.6.1 SCY-635 (SCYNEXIS)
6.6.2 Miraversen (Santaris)
6.6.3 GS-9620 (Gilead Sciences)
6.6.4 RG-101 (Regulus Therapeutics)
6.7 Hepatitis C Pipeline Candidates on Hold or Discontinued, 2014
6.7.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophin Inhibitor
6.7.2 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.7.3 Idenix Developments Terminated: IDX-189 and IDX-19368
6.7.4 Deleobuvir (Boehringer Ingelheim): Development Discontinued
6.7.5 Faldaprevir (Boehringer Ingelheim): Exiting the Hepatitis C Market
6.8 Leading Hepatitis C Vaccine Pipeline Candidates, 2014
6.8.1 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.8.2 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
6.8.3 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
6.8.4 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates

7. Leading Companies in the Hepatitis C Therapies Market
7.1 Leading Market Players, 2013 and 2014
7.2 Gilead Sciences
7.2.1 Product Overview and Performance. 2013 and 2014
7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
7.2.3 Hepatitis Pipeline: Strong and Diverse
7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
7.3 Johnson & Johnson (Janssen Pharmaceuticals)
7.3.1 Product Overview and Performance, 2013 and 2014
7.3.2 Recent Developments: Acquisition of Alios BioPharma
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook: Combination Regimens with Olysio
7.4 Roche
7.4.1 Product Overview and Performance. 2013 and 2014
7.4.2 Recent Developments: Partnership with Anadys
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.5 Bristol-Myers Squibb
7.5.1 Product Overview and Performance. 2013 and 2014
7.5.2 Recent Developments: Strengthening Product Pipeline through Acquisitions
7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.5.4 Future Outlook: Market Set For Intense Competition
7.6 Merck & Co.
7.6.1 Product Overview and Performance. 2013 and 2014
7.6.2 Recent Developments: Merck & Co. Acquires Idenix
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
7.7 Leading Hepatitis C Pipeline Companies, 2014
7.7.1 Gilead Sciences
7.7.2 Merck & Co.
7.7.3 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
7.7.4 Achillion Pharmaceuticals: Next Target for Acquisition
7.7.4.1 Achillion and Gilead

8. Hepatitis C Therapies Market: Industry Trends, 2015-2025
8.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2014-2025
8.1.1 Interferon Therapy Has Drawbacks
8.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2014-2025
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of The World Hepatitis C Therapies Market, 2014-2025
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis C Vaccines
8.5 Oral Direct-Acting Antivirals
8.5.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.5.2 Combining Protease and Polymerase Inhibitors
8.5.3 The Need for Ribavirin
8.5.4 Twelve-Week Treatment Target
8.6 Pharmaceutical Investment in Hepatitis C
8.6.1 Licensing and Partnering Deals
8.6.2 Acquisitions in Hepatitis C
8.6.3 Other Companies of Note for Hepatitis Treatment Developments

9. Research Interviews
9.1 Expert Interview 1: Authority from a Company in the Industry (Views Provided Anonymously)
9.1.1 The Hepatitis C Therapies Market Landscape
9.1.2 Interferon Therapies
9.1.3 The Future Hepatitis C Therapies Market
9.2 Interview with Susan Simon, President of the Hepatitis C Association
9.2.1 Barriers to Treatment
9.2.2 Changes to Treatment in the Past Decade and Coming Years
9.2.3 Support and Awareness for Hepatitis C

10. Conclusions
10.1 State of The Hepatitis Therapies Market, 2013 and 2014
10.2 Growth in The Hepatitis Therapies Market, 2014-2025
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Asia as a Hepatitis C Therapies Market
10.3 Concluding Remarks

List of Tables
Table 1.1 Submarket Forecasts of Hepatitis C Therapies, 2013-2019
Table 1.2 Submarket Forecasts of Hepatitis C Therapies, 2019-2025
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Global Pattern of Hepatitis C Genotypes and Subtypes, 2014
Table 2.2 Approved Antiviral Subtypes for Hepatitis C, 2014
Table 3.1 Hepatitis C Therapies Market ($bn and %) by Sector, 2013
Table 3.2 Hepatitis C Therapies Market ($bn and %) by Sector, 2014
Table 3.3 Hepatitis C Therapies Market: Overall Market Forecast of Currently Approved Drugs and Predicted Approvals ($bn), 2014-2025
Table 3.4 Hepatitis C Therapies Market: Revenue Forecasts by Segment ($bn), 2014-2025
Table 3.5 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging National Markets, 2013
Table 3.6 Leading Hepatitis C Antivirals: Revenue Shares by Drug ($bn and %), 2013
Table 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.8 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2013
Table 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.10 Hepatitis C Submarket Shares (%), 2013, 2019 & 2025
Table 4.1 Global Prevalence of Chronic Hepatitis C, 2013
Table 4.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Region, 2013
Table 4.3 Hepatitis C Therapies: Overall Market and Revenue Forecasts ($bn) by Region, 2014-2025
Table 4.4 US Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.5 EU5 Hepatitis C Therapies: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2013
Table 4.6 EU5 Hepatitis C Therapies Market: Overall Revenue Forecast ($bn), 2014-2025
Table 4.7 Italian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.8 Spanish Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.9 German Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.10 UK Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.11 French Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.12 Chinese Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.13 Japanese Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.14 Indian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.15 Russian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.16 Brazilian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 5.1 Selected Leading Hepatitis C Therapies ($bn and %), 2013
Table 5.2 Sovaldi: Key Facts, 2014
Table 5.3 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
Table 5.4 Sovaldi: Revenue Forecast ($bn), 2014-2025
Table 5.5 Olysio: Key Facts, 2014
Table 5.6 Olysio: Revenue ($bn) by Region, Q1-Q3, 2014
Table 5.7 Olysio: Revenue Forecast ($bn), 2014-2025
Table 5.8 Pegasys: Key Facts, 2014
Table 5.9 Pegasys: Revenue Forecast ($bn), 2014-2025
Table 5.10 Incivek: Key Facts, 2014
Table 5.11 Incivek: Revenue ($bn) and Market Share (%) by Region, 2013
Table 5.12 Incivek: Revenue Forecast ($bn), 2014-2025
Table 5.13 PegIntron: Key Facts, 2014
Table 5.14 PegIntron: Revenue Forecast ($bn), 2014-2025
Table 5.15 Victrelis: Key Facts, 2014
Table 5.16 Victrelis: Revenue Forecast ($bn), 2014-2025
Table 5.17 Harvoni: Key Facts, 2014
Table 5.18 Harvoni: Revenue Forecast ($bn), 2014-2025
Table 5.19 Daklinza: Key Facts, 2014
Table 5.20 Daklinza: Revenue Forecast ($bn), 2014-2025
Table 5.21 Sunvepra: Key Facts, 2014
Table 5.22 Sunvepra: Revenue Forecast ($bn), 2014-2025
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II & III, 2014
Table 7.1 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2013
Table 7.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2014
Table 7.3 Gilead Sciences: Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
Table 7.4 Gilead Sciences: Hepatitis C Pipeline, 2014
Table 7.5 Roche: Hepatitis C Pipeline, 2014
Table 7.6 Pegasys: Revenue ($bn) and Market Share (%), 2013, 2019 & 2025
Table 7.7 Bristol-Myers Squibb: Hepatitis Pipeline, 2014
Table 7.8 Merck & Co.: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
Table 7.9 Gilead Sciences: Hepatitis C All-Oral Regimens, 2014
Table 7.10 Merck & Co.: Hepatitis C All-Oral Regimens, 2014
Table 7.11 AbbVie: Hepatitis C All-Oral Regimens, 2014
Table 7.12 Achillion Pharmaceuticals: Hepatitis C All-Oral Regimens, 2014
Table 8.1 Hepatitis C Therapies Market: Strengths and Weaknesses, 2014
Table 8.2 Hepatitis C Therapies Market: Opportunities and Threats, 2014-2025
Table 8.3 Liver Cancer: Deaths by Region, 2012
Table 8.4 Selected All-Oral Hepatitis C Regimens in Development, 2014
Table 10.1 Hepatitis C Therapies: Revenue ($bn) by Drug and Segment, 2013, 2019 & 2025
Table 10.2 Leading Hepatitis Treatments: Patent Expiries and Peak Revenues ($bn)

List of Figures
Figure 1.1 Hepatitis C Market Segmentation, 2014
Figure 2.1 Brief History of Hepatitis, 1947-2014
Figure 3.1 Hepatitis C Therapies Market by Segment (%), 2013
Figure 3.2 Hepatitis C Therapies Market by Segment (%), 2014
Figure 3.3 Hepatitis C Therapies Market: Overall Market Forecast ($bn), 2014-2025
Figure 3.4 Global Hepatitis C Therapies Market: Drivers and Restraints, 2014-2025
Figure 3.5 Leading Hepatitis C Antivirals Submarket Share (%), 2013
Figure 3.6 Oral Antivirals Market: Drivers and Restraints, 2014-2025
Figure 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.8 Interferons Submarket: Market Share (%) by Drug, 2013
Figure 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.10 Interferons Submarket: Drivers and Restraints, 2014-2025
Figure 3.11 Hepatitis C Submarket Shares ($bn), 2013, 2019 & 2025
Figure 4.1 Chronic Hepatitis C: Global Prevalence (%) by Region, 2013
Figure 4.2 Hepatitis C Therapies: Market Share (%) by Region, 2013
Figure 4.3 Hepatitis C Therapies: Market Share (%) by Region, 2019
Figure 4.4 Hepatitis C Therapies: Market Share (%) by Region, 2025
Figure 4.5 US Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.6 EU5 Hepatitis C Therapies: Market Share (%) by Country, 2013
Figure 4.7 EU5 Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.8 Italian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.9 Spanish Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.10 German Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.11 UK Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.12 French Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.13 Chinese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.14 Japanese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.15 Indian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.16 Russian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.17 Brazilian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 5.1 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
Figure 5.2 Sovaldi: Revenue Forecast ($bn), 2014-2025
Figure 5.3 Olysio: Recent Revenue ($bn), Q1-Q3, 2014
Figure 5.4 Olysio: Revenue Forecast ($bn), 2014-2025
Figure 5.5 Pegasys: Revenue ($bn), 2011-2014
Figure 5.6 Pegasys: Revenue Forecast ($bn), 2014-2025
Figure 5.7 Incivek: Market Share (%) by Region, 2013
Figure 5.8 Incivek: Revenue Forecast ($bn), 2014-2025
Figure 5.9 PegIntron: Recent Revenue ($bn), 2011-2014
Figure 5.10 PegIntron: Revenue Forecast ($bn), 2014-2025
Figure 5.11 Victrelis: Recent Revenue ($bn), 2011-2014
Figure 5.12 Victrelis: Revenue Forecast ($bn), 2014-2025
Figure 5.13 Harvoni: Revenue Forecast ($bn), 2014-2025
Figure 5.14 Daklinza: Revenue Forecast ($bn), 2014-2025
Figure 5.15 Sunvepra: Revenue Forecast ($bn), 2014-2025
Figure 7.1 Hepatitis C Therapies: Market Share (%) by Company, 2013
Figure 7.2 Hepatitis C Therapies: Market Share (%) by Company, 2014
Figure 7.3 Gilead Sciences: Revenue Share (%) by Therapeutic Area, 2013
Figure 7.4 Johnson & Johnson: Key Events in the Hepatitis C Drug Market, 2011-2014
Figure 7.5 Pegasys: Revenue ($bn), 2013, 2019 & 2025
Figure 7.6 Merck & Co.: Revenue Share (%) by Therapeutic Area, 2013
Figure 8.1 Liver Cancer: Deaths by Region, 2012
Figure 10.1 Hepatitis C Therapies: Revenue ($bn) by Segment, 2013, 2019 & 2025

【レポートのキーワード】

C型肝炎(Hepatitis C)、治療薬、パイプライン、研究開発、製薬

★調査レポート[C型肝炎(Hepatitis C)治療薬の世界市場] ( Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025 / VGAIN4121902) 販売に関する免責事項
[C型肝炎(Hepatitis C)治療薬の世界市場] ( Hepatitis C Therapies: World Industry, R&D And Market Forecasts 2015-2025 / VGAIN4121902) についてEメールでお問い合わせ
◆関連調査資料◆
  • 世界の炎症性腸疾患(IBD)治療薬市場
  • 世界の抗がん剤市場：治療法、研究開発動向及び市場予測
  • 世界におけるエピジェネティクスの研究開発、治療薬、診断製品市場
  • 世界の癌治療用キナーゼ阻害剤市場：Brc-Abl阻害剤/EGFR阻害剤/血管新生阻害剤/BRAF・MEK阻害剤/mTOR阻害剤など
  • 世界におけるバイオシミラー及び後続生物製剤市場（2014-2024）
  • 次世代バイオロジックス（生物製剤）市場：技術、産業、市場（2014-2024）
  • 世界の喘息及びCOPD（慢性閉塞性肺疾患）治療薬市場
  • 世界の神経調節用医療装置市場：脊髄刺激療法(SCS)、脳深部刺激療法（DBS）、迷走神経刺激療法(VNS)、仙骨神経刺激療法(SNS)
  • OTC医薬品（一般用医薬品）の世界市場
  • 世界の鎮痛剤（痛み止め）市場予測：麻薬性鎮痛薬/非麻酔鎮痛薬/神経因性疼痛薬/抗片頭痛薬/抗関節炎薬

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆